INTRODUCTION

Tumor necrosis factor ( TNF ) was first isolated in 1975, as a factor with the potential to kill tumor cell lines in vitro. 1 In addition, two other factors with similar physiological activity were identified, and designated as lymphotoxin α and β (LT-a, LT-b)
. [2] [3] [4] TNFs are believed to play an important role in host defense against infections and tumor development . 4, 5 However, accumulating evidence has suggested that overproduction of TNFs is closely related to the pathogenesis of inflammatory disorders such as rheumatoid arthritis (RA), Crohn's disease, and other inflammatory diseases . 6, 7 Subsequently , much effort has gone into the development of therapeutic agents , which target TNFs . These efforts have resulted in anti-TNF biological agents , which have shown dramatic improved outcomes in RA patients as well as in patients suffering from other inflammatory disorders of unknown etiology . 8, 9 These biological agents , which directly target the inflammatory cytokines have revolutionized our strategy in the management of such diseases. 10 
ACTION AND STRUCTURE OF TNFα
TNF binds to specific TNF receptors ubiquitously expressed on the surface of cells throughout the body, and has a long list of physiological actions. 4,5 An excess amount of TNFα in the serum can alter the anticoagulant activity of the endothelial cells and rewul in the induction of hemorrhage, vasodilatation, and neutrophil activation , all prominent features of septic shock. On the other hand, a small but significant increase in the long term concenration of TNFα may
evoke inflammatory responses , such as fever , anemia , body weight loss , and even osteoclast activation. 7 Among tumor necrosis factors, TNFα and TNFβ 
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TNFα consists of homotrimers of TNFα, TNFβ consists of homotrimers of TNFβ (LTα), and lymphotoxinB is a combined from of LT-α and LT-β1. TNFα and TNFβ can bind to two kinds of TNF receptors, namely TNF receptor I (p55) and TNF receptor II ( p75 ) . The unique heterotrimers, consisting of two molecules of LT-α and one molecule of LT-β binds to the third receptor, designated as LT-βR. It has long been thought that each of the receptor molecules exists independently, and assemble during ligand binding. This model is known as the " ligand-induced trimerization " model . Since signal transduction occurs independently, depending on the individual class of receptor
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We g e n e r ' s g r a n u l o ma t o s i s 8 2 -8 4 , g i a n t c e l l a r t e r i t i s 64 Seventy-five percent of these patients developed tuberculosis within the first 6 weeks (3 infusions), and the incidence was higher in endemic regions , suggesting that its appearance was due to reactivation of latent tuberculosis. 64 Although the incidence of tuberculosis in RA patients treated with etanercept appeared to be at the upper limit of the normal controls. 65 It is reported that the risk can be seen in patients treated with adalimumab (Table 3) . Since infliximab and adalimumab are believed to lyse TNFexpressing macrophages (Fig. 1) , which play an indispensable role in host defense against Mycobacterium infection, 64 64, 65 Following implementation of this screening, the incidence of tuberculosis in patients being treated with anti-TNF biologicals was reportedly even lower than in prior studies. 62 
On the other hand , injections of etanercept may lead to local reactions, reportedly in 40 45% of patients. 49 The reactions have usually been mild, and most of them appear to resolve spontaneously or with appropriate management such as rotation of the injection site or anti-histamines. It has been shown that anti-neutralizing antibodies have never been developed , although anti-etanercept antibodies could be detected to some extent It is interesting to note that human anti-human antibodies (HAHA) or anti-idiotypic antibodies could be detected in patients treated with adalimumab, and the frequency appears to be 1 12%. Furthermore , antineutralizing antibodies have been observed with a frequency of around 5% , in spite of the fact that adalimumab is a full human genetically engineered product. Concomitant use of MTX should reduce the frequency, as in the case of infliximab
INFECTIONS
A series of basic experiments have indicated that blockade of TNF-α results in serious infectious diseases caused by intra-cellular pathogens such as
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larities and dissimilarities of the opportunistic infections between Western countries and Japan.
AUTOIMMUNITY
It has been reported that infliximab and etanercept can induce production of anti-nuclear antibodies and anti-DNA antibodies , although the titer of the antibodies remains low. 69, 70 In the earlier studies, the increased risk for developing SLE had been seriously considered . However , the incidence of the disease has not been significantly elevated in the treatment group and it is not a severe life-threatening disease even if it does develop. [71] [72] [73] [74] On the other hand, the risk for demyelinating diseases such as multiple sclerosis and optic neuritis 75, 76 
CONGESTIVE HEART DISEASES
Since it has been proposed that TNF-α has a role in the pathogenesis of heart failure, clinical trials of infliximab and etanercept have been conducted for patients with congestive heart failure . 79 In contrast to the earlier expectation, the mortality rate in patients using higher amounts of infliximab has become evidently higher than that of the placebo group, 79 and no significant benefit was reported in the etnaercept treatment group. 80, 81 99 while others reported results to the contrary, 100 Similar approaches are used in Crohn's disease. [101] [102] [103] Given 
